El-Hattab AW, Scaglia F. Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options. Neurotherapeutics. 2013;10(2):186–98.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Garone C, Taylor RW, Nascimento A, et al. Retrospective natural history of thymidine kinase 2 deficiency. J Med Genet. 2018;55(8):515–21.

Article  CAS  PubMed  Google Scholar 

Amtmann D, Gammaitoni AR, Galer BS, et al. The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of life. Mitochondrion. 2023;68:1–9.

Article  CAS  PubMed  Google Scholar 

Domínguez-González C, Chiang C, Colson AO, et al. Pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency: a multicenter retrospective chart review study. Neurology. 2025;105(6):e213908.

Article  PubMed  PubMed Central  Google Scholar 

Child Neurology Foundation. Thymidine kinase 2 deficiency (TK2d). 2025. https://www.childneurologyfoundation.org/. Accessed 12 Dec 2025.

Lopez-Gomez C, Levy RJ, Sanchez-Quintero MJ, et al. Deoxycytidine and deoxythymidine treatment for thymidine kinase 2 deficiency. Ann Neurol. 2017;81(5):641–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Modis Therapeutics. Modis Therapeutics announces $30M Series A financing [media release]. 1 Oct 2018. http://www.modistx.com.

Modis Therapeutics. Modis Therapeutics announces PRIME Designation granted by the European Medicines Agency to MT1621 for the treatment of TK2 deficiency [media release]. 13 Nov 2018. http://www.modistx.com.

Modis Therapeutics. Modis Therapeutics announces that MT1621 receives Breakthrough Therapy Designation from FDA for the treatment of TK2 deficiency [media release]. 19 Feb 2019. http://www.modistx.com.

UCB. On growth path for a decade plus: strong launch execution driving company growth [media release]. 27 Feb 2025. http://www.ucb.com.

UCB. U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d) [media release]. 3 Nov 2025. https://www.ucb.com/newsroom/press-releases/article/us-fda-approves-kygevvir-doxecitine-and-doxribtimine-the-first-and-only-treatment-for-adults-and-children-living-with-thymidine-kinase-2-deficiency-tk2d.

US Food & Drug Administration. FDA approves 1st drug for thymidine kinase 2 deficiency, a very rare mitochondrial disease [media release]. 3 Nov 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-1st-drug-thymidine-kinase-2-deficiency-very-rare-mitochondrial-disease.

UCB I. KYGEVVI (doxecitine and doxribtimine) powder, for oral solution: US prescribing information. 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219792s000lbl.pdf. Accessed 12 Dec 2025.

Mittur A, VanMeter SA, Orujov E, et al. Pharmacokinetics and safety of a 1:1 mixture of doxecitine and doxribtimine: open-label phase 1 single ascending dose and food effect studies in healthy adults. Clin Ther. 2024;46(7):576–87.

Article  CAS  PubMed  Google Scholar 

Mittur A, Santiago P, Golding M. In vitro evaluation of drug–drug interaction potential of doxecitine and doxribtimine in thymidine kinase 2 deficiency (TK2d) [abstract no. P037]. Genet Med Open. 2025;3(Suppl 2):20–1.

Google Scholar 

Hirano M, Garone C, Haas R, et al. Survival analyses in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy [abstract no. P257 plus poster]. In: Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. 2025.

Garone C, Hirano M, Haas R, et al. Functional outcomes in patients with thymidine kinase 2 deficiency aged ≤12 years at symptom onset who received pyrimidine nucleos(t)ide therapy [abstract no. P255 plus poster]. In: Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. 2025.

Scaglia F, Hirano M, Garone C, et al. Survival and functional outcomes in patients with thymidine kinase 2 deficiency aged >12 years at symptom onset who received pyrimidine nucleos(t)ides [abstract no. P256 plus poster]. In: Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. 2025.

Domínguez-González C, Garone C, Haas R, et al (2025) Safety of pyrimidine nucleos(t)ide therapy in thymidine kinase 2 deficiency: an integrated analysis from a pooled dataset [abstract no 71P]. Neuromuscul Disord. 53(Suppl):105.